Scholarlink

Introduction <p>Topical corticosteroids are regarded as the first-line therapy for chronic hand eczema (CHE), despite a lack of substantial evidence from randomized controlled trials to confirm their efficacy. Topical benvitimod is a potential alternative for long-term maintenance.</p> Methods <p>A prospective, single-center, open-label randomized trial was conducted, using a parallel-group design and enrolling 64 patients who had moderate-to-severe CHE. Patients were randomly divided into two treatment groups: 32 patients used 1% benvitimod cream twice a day for 8&#xa0;weeks, whereas the other 32 patients received halometasone cream on the same application schedule and duration. The percentage of patients who achieved “treatment success” at week&#xa0;12 was the primary endpoint. Secondary endpoints included changes in physician-assessed Hand Eczema Severity Index (HECSI), patient-reported subjective scores, the relapse rate, and adverse events. Patient-reported subjective scores included Patient Global Assessment (PaGA), Dermatology Life Quality Index (DLQI), and Quality of Life in Hand Eczema Questionnaire (QOLHEQ).</p> Results <p>Fifty-nine patients completed the trial (30 in the benvitimod group and 29 in the halometasone group). The treatment success rate was 26.7% (8/30) in the benvitimod group and 24.1% (7/29) in the halometasone group (<i>p</i> = 0.824) at week&#xa0;12. From baseline to week&#xa0;12, the two groups demonstrated significant reductions in HECSI, PaGA, DLQI, and QOLHEQ scores (<i>p</i> &lt; 0.05). However, no statistically significant differences were observed between the two groups. Among patients who achieved treatment success, 25.0% (2/8) patients in the benvitimod group and 57.1% (4/7) patients in the halometasone group relapsed at week&#xa0;24 (<i>p</i> = 0.315). The main adverse events associated with benvitimod were skin pigmentation, pruritus, and skin dryness, none of which led to treatment discontinuation.</p> Conclusions <p>Benvitimod exhibits efficacy comparable to halometasone in managing moderate-to-severe CHE, along with a favorable safety and a low relapse rate.</p> Trial Registration Number <p>ChiCTR2100051948.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and Safety of Benvitimod Compared with Halometasone in Patients with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Yuan Chang,
  • Gongfeng Tang,
  • Haixuan Wu,
  • Xuelei Liang,
  • Yi Liu,
  • Fenglin Zhuo

摘要

Introduction

Topical corticosteroids are regarded as the first-line therapy for chronic hand eczema (CHE), despite a lack of substantial evidence from randomized controlled trials to confirm their efficacy. Topical benvitimod is a potential alternative for long-term maintenance.

Methods

A prospective, single-center, open-label randomized trial was conducted, using a parallel-group design and enrolling 64 patients who had moderate-to-severe CHE. Patients were randomly divided into two treatment groups: 32 patients used 1% benvitimod cream twice a day for 8 weeks, whereas the other 32 patients received halometasone cream on the same application schedule and duration. The percentage of patients who achieved “treatment success” at week 12 was the primary endpoint. Secondary endpoints included changes in physician-assessed Hand Eczema Severity Index (HECSI), patient-reported subjective scores, the relapse rate, and adverse events. Patient-reported subjective scores included Patient Global Assessment (PaGA), Dermatology Life Quality Index (DLQI), and Quality of Life in Hand Eczema Questionnaire (QOLHEQ).

Results

Fifty-nine patients completed the trial (30 in the benvitimod group and 29 in the halometasone group). The treatment success rate was 26.7% (8/30) in the benvitimod group and 24.1% (7/29) in the halometasone group (p = 0.824) at week 12. From baseline to week 12, the two groups demonstrated significant reductions in HECSI, PaGA, DLQI, and QOLHEQ scores (p < 0.05). However, no statistically significant differences were observed between the two groups. Among patients who achieved treatment success, 25.0% (2/8) patients in the benvitimod group and 57.1% (4/7) patients in the halometasone group relapsed at week 24 (p = 0.315). The main adverse events associated with benvitimod were skin pigmentation, pruritus, and skin dryness, none of which led to treatment discontinuation.

Conclusions

Benvitimod exhibits efficacy comparable to halometasone in managing moderate-to-severe CHE, along with a favorable safety and a low relapse rate.

Trial Registration Number

ChiCTR2100051948.